Skip to main content

Advertisement

Log in

Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, has recently been added to the therapeutic armamentarium against rheumatoid arthritis (RA). Despite its overall safety, concerns have been raised regarding diverticular perforation in patients receiving the drug. The aim of our research was to document the incidence of diverticular disease in RA patients treated in the pre-disease-modifying anti-rheumatic drug (DMARD) era, following treatment with conventional DMARDs, and subsequent to tocilizumab therapy. We performed a systematic literature review in MEDLINE, EMBASE, Conference Proceedings Citation Index–Science, Cochrane Central Register of Controlled Trials and Current Controlled Trials up to Nov. 2010. The publication titles and abstracts were independently assessed by two reviewers for relevance and quality, and the review was conducted following guidelines from the Centre for Reviews and Dissemination. In the pre-DMARD period of RA management, where patients were largely treated with NSAIDs and corticosteroids, gastrointestinal (GI) complications were a substantial cause of mortality with diverticulitis and colonic ulcers accounting for almost a third of GI-related deaths. In contrast, our search did not reveal any evidence of diverticular perforation in patients treated with conventional DMARDs. Eighteen cases of lower GI perforation (16 of whom had diverticulitis) have been documented in recent conference proceedings following tocilizumab treatment in clinical trials, with a lower GI perforation rate of 1.9 per 1,000 patient years (PY). This lies between the reported rate of GI perforations for corticosteroids and anti-TNF-α agents in the United Health Care database, with rates of 3.9 per 1,000 PY (95% CI 3.1–4.8) and 1.3 per 1,000 PY (95% CI 0.8–1.9), respectively. The majority of these patients were concurrently prescribed NSAIDs and/or long-term corticosteroids. Traditional DMARD therapy for RA appears not only to have modified the risk of lower GI perforation but prevented it. The risk of diverticular perforation may be slightly higher in patients treated with tocilizumab compared with conventional DMARDs or anti-TNF agents, but lower than that for corticosteroids. The mechanism of action of IL-6 antagonism in the pathophysiology of diverticular perforation has yet to be elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wolfe F, Rasker JJ, Boers M et al (2007) Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 57:935–942

    Article  PubMed  Google Scholar 

  2. Haraoui B (2005) The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol 72:46–47

    Google Scholar 

  3. Hyrich KL, Silman AJ, Watson KD et al (2004) Anti-tumour necrosis factor a therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63:1538–1543

    Article  PubMed  CAS  Google Scholar 

  4. Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523

    Article  PubMed  CAS  Google Scholar 

  5. Centre for Reviews and Dissemination (2011) Systematic reviews. Centre for Reviews and Dissemination guidance for undertaking reviews in health care. http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf. Accessed 5 Aug 2011

  6. Prior P, Symmons DPM, Scott DL et al (1984) Cause of death in rheumatoid arthritis. Rheumatology 23:92–99

    Article  CAS  Google Scholar 

  7. Allbeck P, Ahlbom A, Allander E (1981) Increased mortality among persons with rheumatoid arthritis but where RA does not appear on the death certificate. Scand J Rheumatol 10:301–306

    Article  Google Scholar 

  8. Curtis JR, Xie F, Chen L et al (2011) The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 63:346–351

    Article  PubMed  Google Scholar 

  9. Mpofu S, Mpofu CM, Hutchinson D et al (2004) Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 63:588–590

    Article  PubMed  CAS  Google Scholar 

  10. Foutch PG (1995) Diverticular bleeding: are nonsteroidal anti-inflammatory drugs risk factors for hemorrhage and can colonoscopy predict outcome for patients? Am J Gastroenterol 90:1779–1784

    PubMed  CAS  Google Scholar 

  11. Peura DA, Lanza FL, Gostout CJ et al (1997) The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol 92:924–928

    PubMed  CAS  Google Scholar 

  12. Goh H, Bourne R (2002) Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study. Ann R Coll Surg Engl 84:93–96

    PubMed  CAS  Google Scholar 

  13. Laine L, Smith R, Min K et al (2006) Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 24:751–767

    Article  PubMed  CAS  Google Scholar 

  14. Eaves R, Hansky J, Wallis P (1982) Gold induced enterocolitis: case report and a review of the literature. Aust N Z J Med 12:617–620

    Article  PubMed  CAS  Google Scholar 

  15. Corsi F, Previde P, Colombo F et al (2006) Two cases of intestinal perforation in patients on anti-rheumatic treatment with etanercept. Clin Exp Rheumatol 24:113

    PubMed  CAS  Google Scholar 

  16. Piekarek K, Israelsson LA (2008) Perforated colonic diverticular disease: the importance of NSAIDs, opioids, corticosteroids, and calcium channel blockers. Int J Colorectal Dis 23:1193–1197

    Article  PubMed  Google Scholar 

  17. Van Vollenhoven RF, Keystone EC, Furie R et al (2009) Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: data from Roche clinical trials [abstract]. Arthritis Rheum 60 Suppl:S602

    Google Scholar 

  18. Hughes LE (1969) Postmortem survey of diverticular disease of the colon. I. Diverticulosis and diverticulitis. Gut 10:336–344

    Article  PubMed  CAS  Google Scholar 

  19. Morris CR, Harvey IM, Stebbings WS et al (2003) Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg 90:1267–1272

    Article  PubMed  CAS  Google Scholar 

  20. Hart AR, Kennedy HJ, Stebbings WS et al (2000) How frequently do large bowel diverticula perforate? An incidence and cross-sectional study. Eur J Gastroenterol Hepatol 12:661–665

    Article  PubMed  CAS  Google Scholar 

  21. Hernandez-Diaz S, Rodriguez LA (2002) Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 55:157–163

    Article  PubMed  Google Scholar 

  22. Morris CR, Harvey IM, Stebbings WS et al (2008) Incidence of perforated diverticulitis and risk factors for death in a UK population. Br J Surg 95:876–881

    Article  PubMed  CAS  Google Scholar 

  23. Chan FKL, Cryer B, Goldstein JL et al (2010) A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 37:167–174

    Article  PubMed  CAS  Google Scholar 

  24. Lanas A (2010) A review of gastrointestinal safety data—a gastroenterologist’s perspective. Rheumatology 49:3–10

    Article  Google Scholar 

  25. Allbeck P (1982) Increased mortality in rheumatoid arthritis. Scand J Rheumatol 11:81–86

    Article  Google Scholar 

  26. Takeuchi K, Kuroda Y (2000) Rheumatoid vasculitis with multiple intestinal ulcerations: report of a case. Ryumachi 40:639–643

    PubMed  CAS  Google Scholar 

  27. Petersen P, Christiansen P, Jensen P (1983) Mesenterial rheumatoid arteritis. A case of ischemic necrosis of small intestine. Ugeskr Laeger 145:1689–1690

    PubMed  CAS  Google Scholar 

  28. Hay JM, Testart J (1974) Periarteritis nodosa and colonic perforation. J Chir 107:313–315

    CAS  Google Scholar 

  29. Kawashima I, Matsuoka Y, Fukuda J et al (1996) A case of perforated appendix caused by secondary amyloidosis associated with rheumatoid arthritis. Jpn J Gastroenterol 93:569–572

    CAS  Google Scholar 

  30. Leifeld L, Kruis W (2008) Modern therapy of diverticular disease. Internist 49:1415–1416

    Article  PubMed  CAS  Google Scholar 

  31. Pham T, Claudepierre P, Constantin A et al (2010) Tocilizumab: therapy and safety management. Joint Bone Spine 77:S3–S100

    Article  PubMed  Google Scholar 

  32. Khader A, Guglani L (2010) Th17 cytokines in mucosal immunity and inflammation. Curr Opin HIV AIDS 5:120–127

    Article  PubMed  Google Scholar 

  33. Horiuchi T, Mitoma H, Harashima S et al (2010) Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology 49:1215–1228

    Article  PubMed  CAS  Google Scholar 

  34. Kopf M, Bachmann M, Marsland B (2010) Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9:703–718

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Andrew Östör has received support from (including attendance at conferences), undertakes clinical trials for and acts as a consultant to Roche, Chugai, Schering–Plough/MSD, Abbott, Wyeth, BMS, GSK, MerckSorono and UCB. Other authors have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Muhammad K. Nisar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gout, T., Östör, A.J.K. & Nisar, M.K. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 30, 1471–1474 (2011). https://doi.org/10.1007/s10067-011-1827-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-011-1827-x

Keywords

Navigation